616- ADHD Treatment and Substance Use Problems: The Latest Research on Stimulants & SUD
Topics discussed
Sponsor: Vela menopause and intimacy products
Introduction of Dr. Malina and Dr. D'Onofrio
Survey on ADHD and inflammatory disorders
Conflicts of interest and research funding
Domains contributing to ADHD and substance use
Variation in response to rewarding stimuli
Susceptibility to immediately rewarding substances
Temperament, personality, and impulsivity
Knowing vs. doing: ADHD and knowledge
ADHD symptoms as substance use risk factors
Longitudinal study: ADHD and educational attainment
Defining the research question on stimulant treatment
Sponsor: Camelbeach water park
Methodology: Clinical samples and measurement
Understanding confounders in research
Potential confounders in ADHD medication studies
Summary of existing study findings
The MTA study: Design and follow-up
Controlling for age in medication analysis
Sponsor: Vela women's health products
Does longer medication use increase risk?
Results: No increased risk of heavy use
Interpretation: Glass half full vs. half empty
Need for more research on family history
Dr. D'Onofrio: Introduction and large-scale studies
Limitations of other research designs
Analyzing large health insurer data sets
Limitations of randomized controlled trials
Generalizability of RCT participants
Comorbidities and dropout in RCTs
Observational data and confounding variables
Reverse causation and genetic factors
National surveys and research infrastructure
Disadvantages of national survey data
Study design: Exposure and outcome measures
Understanding odds ratios in results
Non-stimulant medication and cocaine risk
Impact of medication duration and age
Findings: Earlier start and longer duration
Advantages of within-individual comparisons
Private insurance data and prescription fills
Emergency department visits for substance use
Risk reduction during medication periods
Protective effects across age groups
Swedish national database study design
Swedish study: Exposure and outcomes
All-cause mortality results
Reduction in accidental poisoning deaths
Consistent findings across subgroups
Summary of large-scale study limitations
Q&A: Treatment barriers for dual diagnosis
Q&A: US guidelines for adult ADHD
Q&A: Hope for future guidelines and training
Q&A: Stimulants for those with addictive personality
Q&A: Summary of evidence on stimulant risk
Q&A: Non-stimulant and psychosocial options
Q&A: Teachers influencing parents on medication
Q&A: Resources for teachers and counselors
Q&A: Women, depression, and substance use
Q&A: Adult diagnosis and severity
Q&A: Co-occurring depression and anxiety
Closing: Accessing event resources
Sponsor: Wellfront cash account
Sponsor: Wellfront features and benefits
Listen ad-free on Castria